Author:
Man Anthony,Segal Florencia
Abstract
Little progress has been made since the 1960s and 1970s to widen the therapeutic arsenal against Trypanosoma cruzi, the causative pathogen of Chagas disease, which remains a frustrating and perplexing infectious disease. This chapter focuses on the strategic and operational challenges in the clinical drug development of a novel antitrypanosomal agent for Chagas disease. The various elements that contribute to a robust assessment of treatment effect including dose selection, choice of patient population, trial methodology, endpoint measures, and regulatory perspectives are discussed. The learnings herein should serve as resource to help researchers and other stakeholders optimize their clinical development plans and speed delivery of new medicines to patients with Chagas disease.
Reference84 articles.
1. Chagas’ disease (Also Known as American Trypanosomiasis). WHO Fact Sheets. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/Chagas’-disease-(american-trypanosomiasis)
2. Echeverria LE, Marcus M, Novick G, et al. WHF IASC roadmap on Chagas’ disease. Global Heart. 2020;15(1):26
3. Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas’ disease in Latin-American migrants living in Europe: A systematic review and Meta-analysis. PLoS Neglected Tropical Diseases. 2015;9(2):e0003540
4. Pérez-Molina JA, Norman N, López-Vélez R. Chagas’ disease in non-endemic countries: Epidemiology, clinical presentation and treatment. Current Infectious Disease Reports. 2012;14:263-274
5. Lee BY, Bacon KM, Bottazzi ME, et al. Global economic burden of Chagas’ disease: A computational simulation model. The Lancet Infectious Diseases. 2013;13:342-348
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Chagas Disease;Rising Contagious Diseases;2024-01-05